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Highlights 
 NICTH is a rare cause of hypoglycaemia however it is one which is likely to be 
underdiagnosed. 
 NICTH, is seen with an ever-increasing number of malignancies and will be more frequent in 
the future considering the increased survival of patients with cancer. 
 NICTH is characterized by low levels of insulin, C-peptide, proinsulin, and beta-
hydroxybutyrate. A ratio of IGF-2/IGF-1 higher than 10 confirms NICTH. 
 Curative treatment of NICTH remains surgical removal of the primary disease. In certain 
malignancies (GIST), targeted cytoreductive treatment is appropriate to alleviate symptoms of 
NICTH. 
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 Abstract: 
 We report the case of a 79-year-old male with previous history of non-Hodgkin‟s 
lymphoma in remission, who presented acutely to the Accident and Emergency department 
with recurrent episodes of hypoglycaemia. At the time of presentation, a random glucose was 
low at 1.4 mmol/l, which upon correction resolved his symptoms. In hindsight, the patient 
recalled having had similar episodes periodically over the past 2 months to which he did not 
give much notice. While hospitalized, he continued having episodes of symptomatic 
hypoglycaemia, requiring treatment with intravenous dextrose and per os steroids. Once 
stable, he was discharged on oral prednisolone and dietary advice. A computed tomography 
scan performed during inpatient stay showed multiple deposits in the abdomen. An 
ultrasound guided biopsy of one of the liver deposits was performed. Immunohistochemistry 
supported the diagnosis of a gastrointestinal stromal tumour (GIST) positive for CD34 and 
CD117. The diagnosis of non-islet cell tumour hypoglycaemia (NICTH) secondary to an 
IGF2 secreting GIST was confirmed with further biochemical investigations 
(IGF2=105.9 nmol/l; IGF2:IGF1 ratio 23, Upper Level of Normal (ULN) <10). Targeted 
cytoreductive treatment with Imatinib mesylate following assessment of the tumour‟s 
mutational status was successful in preventing hypoglycaemia over a 21-month follow-up 
observation period. 
 
 
Introduction: 
Non-islet cell tumour hypoglycaemia (NICTH) is now thought to be most often due to 
over-secretion of insulin-like growth factor-2 (IGF-2). IGF-2 precursor is secreted by such 
tumours and is less able to bind to circulating binding proteins, such that it can pass through 
capillaries and thus activate the insulin receptor. Malignant neoplasms of mesenchymal and 
epithelial origin may secrete IGF-2, causing in a minority of cases, fasting hypoglycaemia 
characteristic of insulin producing islet cells tumours [1,2]. Diagnosis is confirmed by the 
demonstration of hypoglycaemia in the presence of low levels of serum insulin and an 
elevated IGF-2/IGF-1 ratio, determined using peripheral blood samples. In a recent review by 
Han et al., 76 solid fibrous tumours presenting with NICTH were found in the literature. In 8 
         
cases, there was over-secretion of growth hormone (GH) with only 1 case demonstrating 
decreased concentration. Furthermore, 4 cases reported presence of Insulin Growth Factor 
Binding Protein 3 (IGFBP3), in which 3 cases showed decreased levels, and1case did not 
have a reported value for the normal range of IGFBP3. In cases of manifested 
hypoglycaemia, C-peptide and insulin concentrations were marginally decreased. In 15 out of 
19 cases, the IGF-2/IGF-1 ratio was > 10. In addition, 4 cases reported IGF-2/IGF-1 ratio < 
10, while total IGF-2 concentrations were normal and showed significantly suppressed levels 
of IGF-1 [3]. 
The main treatment for NICTH depends on disease stage at presentation and this can vary 
between surgical excision or selective chemotherapy agents targeting C-kit pathogenic 
variants, with glucocorticoids and other treatments such as growth hormone used for 
symptomatic relief. [4]. Historically GIST has been considered radiation-resistant, and the 
role of radiotherapy in the management of patients with GIST is currently restricted to 
symptomatic palliation in current treatment guidelines [5]. 
 
 
Case report: 
A 79-year-old Caucasian man, with history of follicular grade 2 non-Hodgkin‟s 
lymphoma in remission for more than 5 years following cytoreductive treatment, presented to 
the emergency department with weight loss, reduced appetite and recurrent episodes of 
hypoglycaemia for 2 months preceding admission. At the time of presentation, his HbA1c 
was 34mmol/mol (reference range 29 - 41mmol/mol) and blood glucose 1.4mmol/l (reference 
range 4.0 - 5.6mmol/L) in the absence of glucose-lowering treatment. He was treated for 
hypoglycaemia using a local protocol including administration of intramuscular 1mg 
Glucagon and, once stable with oral dextrose tablets. During his stay, a short Synacthen test 
using 250mcg of intravenously administered tetracosactide was carried out to assess his 
adrenal reserves. His 60-minute cortisol rose above 550nmol/L excluding adrenal 
insufficiency according to Generation II Roche cortisol assay standards used by local 
pathology labs.  
He was discharged with dietary advice and prednisolone 20mg once daily for 4 weeks to 
avoid recurrent hypoglycaemia with clear instructions to reduce the dose gradually until 
         
discontinued and he was reviewed again in the outpatient department. A contrast-enhanced 
CT scan of his abdomen did not demonstrate any pancreatic neoplasms; however revealed 
liver and omental deposits (Fig-1A). A guided biopsy performed at a later stage with 
subsequent immunohistochemistry was positive for CD117 (C-kit), Dog1, CD34 with focal 
expression of SMA, confirming the diagnosis of a metastatic gastrointestinal stromal tumour 
(GIST) (Fig-1B; A-C). Genetic testing for c-kit activating pathogenic variants following 
DNA isolation from paraffin-embedded tissue samples was carried-out to predict his response 
to therapy and guide the anti-CD117 starting dose with imatinib mesylate; this revealed a 
exon 11 deletion [4]. NICTH was suspected, with an IGF-2 (105.9 nmol/l) to IGF-1 (4.6 
nmol/l) ratio of 23 supporting the diagnosis (UNL <10). Following discussion at the upper 
gastrointestinal malignancy multidisciplinary meeting, treatment with imatinib mesylate 
400mg daily was initiated and prednisolone was gradually tapered off. Two months following 
initiation of treatment, there were no further reported hypoglycaemic episodes. Surveillance 
imaging six months after treatment initiation revealed a partial response (Fig-1A) and there 
were no hypoglycaemic episodes for the next 21 months. 
 
Discussion: 
The incidence of NICTH ranges annually from 2.1 to 17 per million people with even 
distribution between genders and is typically seen with large metastatic or mesenchymal 
tumours [2]. NICTH presents as recurrent or persisting hypoglycaemic episodes and mostly 
affects elderly patients with advanced tumours. Occasionally, these hypoglycaemic episodes 
can predate the diagnosis of the underlying tumour, being the presenting symptom that leads 
to diagnosis of an underlying malignancy. NICTH is commonly associated with tumour cell 
production of IGF2. NICTH is characterised by low serum insulin and C-peptide levels, low 
growth hormone (GH) and IGF1 levels, normal or elevated IGF2 levels, and an elevated 
IGF2:IGF1 ratio. When available to measure, expression of „big‟ IGF2 has been reported and 
rarely there is expression of pro-IGF2. High concentrations of pre-pro-IGF2 levels that are 
not properly glycosylated result in the high molecular weight „big‟ IGF2 that has a 
significantly higher affinity to the insulin receptor, and a lower affinity to its binding protein 
(IGFBP3), leading to increased bioavailability, enhanced peripheral glucose consumption and 
suppressed hepatic glucose production [2].  
         
The diagnosis of GIST is confirmed by immunohistochemical staining of CD117 (C-
kit), which is positive in almost 95% of cases [6-7]. Pathogenic variant  analysis in GIST is 
crucial as it identifies less sensitive or resistant genotypes (PDGFR D842V) to selective 
Tyrosine Kinase Inhibitor (TKI) imatinib mesylate and allows dose adjustment for patients 
with c-kit exon 9 pathogenic variants  (800mg daily). This contrasts with the standard dose of 
the most common c-kit exon 11 pathogenic variant which is 400mg daily [7]. Long-term use 
of glucocorticoids may be appropriate for the management of NICTH secondary to other 
mesenchymal neoplasms as these can suppress tumor-specific secretion of “big” IGF-II [3]. 
Surgical removal of the primary tumour remains the most rapid and effective therapy for 
normalising glucose metabolism in most cases of NICTH when indicated.  
NICTH is a poorly recognised cause of hypoglycaemia and consequently may 
frequently remain undiagnosed. This case highlights the importance of recognising NICTH as 
a potential cause of emergency department attendance in cases of patients with advanced 
malignancy and adds to cases confirming GIST as the source of abnormal secretion of IGF-2.  
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Figure legends: 
 
Figure 1A - Radiology legends: 
Pre. Contrast enhanced computerised tomography revealing extensive abdominal disease 
before treatment initiation with Imatinib mesylate. 
Post.  Follow-up computerised tomography 6 months after treatment with Imatinib mesylate 
revealing partial disease response.  
 
 
 
         
Figure 1B - Immunohistochemistry legends 
A. Haematoxylin & Eosin staining, 200X magnification light microscopy showing spindle 
cells arranged in fascicles and fibrillary eosinophilic cytoplasm forming whorls consistent 
with gastrointestinal stromal tumour (GIST). 
B&C. Immunohistochemical studies showing tumour cells diffusely positive for proto-
oncogene c-kit (CD 117) and DOG-1, magnification 200X 
 
 
 
         
